Tirzepatide and sulfur burps: GIP receptor-mediated gastric effects — looking for input

lisa_labSD said:

Almost every unanswerable question in these threads is unanswerable because three things changed in the same fortnight, and no amount of subsequent…

Coming at lisa_labSD’s question from a different direction. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

One concrete data point for the thread. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

A narrower follow-up, since the general answer is now clear:

Whether holding at a lower dose for longer actually reduces total side-effect burden or just spreads it out?

Dr.NateNeph said:

For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

Closing the loop on my own question.

Follow-up: smaller meals, less fat in the two days after dosing, and not lying down afterwards. Unglamorous, and it worked within a fortnight.